◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

ENZON PHARMACEUTICALS, INC.

CIK: 727510 SIC: 2836
-
Revenue
$-3.41M
Net Income
-
Gross Margin
-
Op. Margin
$-4.92M
Free Cash Flow
Financial Statements Annual (10-K)
Showing 10 of 15 annual reports available (2011 - 2025)
Breakdown TTM
(Dec 31, 2025)
FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
FY 2020
(Dec 31, 2020)
FY 2019
(Dec 31, 2019)
FY 2018
(Dec 31, 2018)
FY 2017
(Dec 31, 2017)
FY 2016
(Dec 31, 2016)
+ Total Revenue - - $26.00K - $26.00K $701.00K $52.00K $207.00K $6.92M $8.38M $8.38M
Revenue Growth % nan% nan% nan% nan% -96.3% 1248.1% -74.9% -97.0% -17.4% 0.0% nan%
Operating Expenses $5.31M $5.31M $1.35M $1.04M $1.06M $1.17M $1.36M $1.18M $1.06M $1.37M $1.73M
+ Operating Income $-5.31M $-5.31M $-1.33M $-1.04M $-1.03M $-469.00K $-1.30M $-973.00K - - -
Operating Margin % nan% nan% -5103.8% nan% -3969.2% -66.9% -2509.6% -470.0% nan% nan% nan%
Income Before Tax $-3.39M $-3.39M $1.12M $1.22M $-386.00K $-462.00K $-1.30M $-973.00K $5.86M $7.01M $6.64M
Income Tax Expense $19.00K $19.00K $347.00K $-156.00K $-200.00K $7.00K $7.00K $6.00K $6.00K $1.56M $7.77M
+ Net Income $-3.41M $-3.41M $778.00K $1.37M $-186.00K $-469.00K $-1.31M $-979.00K $5.85M $5.45M $-1.13M
Net Margin % nan% nan% 2992.3% nan% -715.4% -66.9% -2521.2% -472.9% 84.5% 65.0% -13.4%
Basic EPS -0.07 -0.07 -0.01 0.00 -0.02 -0.03 -0.03 nan nan 0.12 -0.03
Diluted EPS -0.07 -0.07 -0.01 0.00 -0.02 -0.03 -0.03 nan nan 0.12 -0.03
Basic Shares Outstanding - 74.2M 74.2M 74.2M 74K 74K 51K - - 44.2M 44.2M
Diluted Shares Outstanding - 74.2M 74.2M 74.2M 74K 74K 51K - - 44.2M 44.2M
Breakdown FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
FY 2020
(Dec 31, 2020)
FY 2019
(Dec 31, 2019)
FY 2018
(Dec 31, 2018)
FY 2017
(Dec 31, 2017)
FY 2016
(Dec 31, 2016)
Cash & Cash Equivalents $42.57M $46.86M $47.01M $46.98M $47.64M $48.14M $5.45M $6.50M $7.48M $7.64M
Other Current Assets $239.00K $293.00K $331.00K $405.00K $85.00K $59.00K $62.00K $70.00K $94.00K $270.00K
Total Current Assets $42.81M $47.15M $47.34M $47.39M $47.75M $48.23M $5.99M $14.54M $7.57M $7.91M
Total Assets $42.81M $47.17M $47.70M $47.59M $47.75M $48.23M $6.48M $15.51M $9.51M $11.27M
Accounts Payable $331.00K $331.00K $331.00K $331.00K $331.00K $302.00K $324.00K $439.00K $225.00K $770.00K
Accrued Liabilities $400.00K $72.00K $108.00K $93.00K $72.00K $110.00K $99.00K $78.00K $143.00K $170.00K
Total Current Liabilities $731.00K $1.68M $1.71M $1.70M $403.00K $412.00K $423.00K $517.00K $368.00K $940.00K
Common Stock $742.00K $742.00K $742.00K $742.00K $742.00K $742.00K $442.00K $442.00K $442.00K $441.00K
Retained Earnings $-73.30M $-69.89M $-70.67M $-72.04M $-71.86M $-71.39M $-70.08M $-69.10M $-74.95M $-80.39M
Total Stockholders Equity $-2.52M $3.01M $-3.50M $3.41M $4.87M $7.36M $6.05M $14.99M $9.14M $10.33M
Total Liabilities & Equity $42.81M $47.17M $47.70M $47.59M $47.75M $48.23M $6.48M $15.51M $9.51M $11.27M
Breakdown TTM
(Dec 31, 2025)
FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
FY 2020
(Dec 31, 2020)
FY 2019
(Dec 31, 2019)
FY 2018
(Dec 31, 2018)
FY 2017
(Dec 31, 2017)
FY 2016
(Dec 31, 2016)
Net Income $-3.93M $-3.41M $778.00K $1.37M $-186.00K $-469.00K $-1.31M $-979.00K $5.85M $5.45M $-1.13M
Deferred Income Tax $101.00K $17.00K $342.00K $-157.00K $-202.00K - - - - $3.36M $7.75M
Operating Cash Flow $-4.92M $-3.01M $1.12M $1.30M $-659.00K $-501.00K $-380.00K $6.91M $-978.00K $6.47M $2.60M
Stock Issued - - - - - - $43.60M - - - -
Dividends Paid $3.83M $1.27M $1.27M $1.27M - - - $7.96M - $6.63M $6.63M
Financing Cash Flow $-3.83M $-1.27M $-1.27M $-1.27M - - $43.08M $-7.96M - $-6.63M $-6.63M
Net Change in Cash $-8.74M $-4.29M $-153.00K $30.00K $-659.00K $-501.00K $42.70M $-1.05M $-978.00K $-161.00K $-4.03M
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Operating Expenses $1.30M - $3.84M -
Operating Income $-1.30M - $-3.84M -
Income Before Tax $-808.00K - $-2.35M -
Income Tax Expense $16.00K - $-7.00K -
Net Income $-824.00K $276.00K $-2.34M -
Basic EPS -0.02 - -0.05 -
Diluted EPS -0.02 - -0.05 -
Basic Shares Outstanding $74.22M - $74.22M -
Diluted Shares Outstanding $74.22M - $74.22M -
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $43.26M $46.86M
Other Current Assets $411.00K $293.00K
Total Current Assets $43.67M $47.15M
Total Assets $43.69M $47.17M
Accounts Payable $331.00K $331.00K
Accrued Liabilities $209.00K $72.00K
Total Current Liabilities $540.00K $1.68M
Common Stock $742.00K $742.00K
Retained Earnings $-72.23M $-69.89M
Total Stockholders Equity $-923.00K $3.01M
Total Liabilities & Equity $43.69M $47.17M
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $-824.00K $276.00K $-2.34M -
Deferred Income Tax $16.00K - $-9.00K -
Operating Cash Flow - - $-2.33M -
Dividends Paid - - $1.27M -
Financing Cash Flow - - $-1.27M -
Net Change in Cash - - $-3.60M -

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-K filings.

Annual data represents full fiscal year results. FY = Fiscal Year ending.

NEWS
Loading news...
TRENDING
Loading...